Significance of tumor markers in lung cancer

Mumbarkar, P. P.; Raste, A. S.; Ghadge, M. S.

doi:10.1007/bf02913090

Cited by 15 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After independent review, 75 publications on the role of pleural CEA concentrations in the diagnosis of MPE were considered to be eligible for inclusion in the analysis 21–95 . Of these publications, two were excluded because they recruited less than 10 patients in one of study groups, 69,70 four were excluded because the CEA concentration was determined only in patients with MPE, 71–74 16 were excluded because they included MPE and malignant peritoneal effusions as a single group, 75–90 two were excluded because they did not allow the calculation of sensitivity or specificity, 91,92 and three were excluded because the same authors published several reports on the same patients, and only the best‐quality study was considered 93–95 …”

Section: Resultsmentioning

confidence: 99%

Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta‐analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…These were further confirmed by the analysis of serum tumor markers. Tumor markers may reflect both the stage of the disease and the prognostic value [48]. Analysis of specific tumor marker serves as an indicator of neoplasm response to therapy.…”

Section: Discussionmentioning

confidence: 99%

“…CEA is a tumor‐associated glycoprotein and one of the onco‐fetal antigens used most widely as a tumor marker in clinical oncology. CK‐19 fragment (CYFRA 21‐1) is a new cytoskeleton marker that measures only the level of CK19 [48,50]. According to Barlesi [51], combinational analysis of CYFRA 21‐1 and CEA markers remained a prognostic determinant value.…”

Section: Discussionmentioning

confidence: 99%

Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene‐induced experimental pulmonary tumorigenesis

Naveenkumar

Asokkumar

Raghunandhakumar

et al. 2011

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Current study aims to evaluate the efficacy of baicalein (BE), a naturally occurring bioactive flavanoid (5,6,7-trihydroxy-flavone), at a dose of 12 mg/kg body wt in Swiss albino mice exposed to tobacco-specific carcinogen benzo(a)pyrene [B(a)P] (50 mg/kg body wt) for its ability to mitigate pulmonary adenoma formation and growth. Under coarse observation, B(a)P-administered mice, after 16 weeks, developed macroscopically detectable tumors, whereas oral treatment with BE to the lung cancer-induced mice significantly reduced tumor incidence in 16-week pre- and posttreated groups. A detailed histopathological examination of lung was conducted to determine the degree of cancer progression. Incidence of anaplasia, hyperplasia, dysplasia, severe dysplasia, and adenocarcinoma were evident in carcinogen-administrated group in 6, 10, 12, 14, and 16th weeks, respectively, whereas these anomalies were effectively reduced after pre- and posttreatment with BE. In the pretreatment group, BE significantly arrested tumor multiplicity by approximately 65% and tumor load by approximately 88%, while in the posttreatment, the compound significantly reduced the tumor multiplicity by approximately 48% and tumor load by approximately 61%. Further analysis of serum tumor markers like carcinoembryonic antigen, CK 19 fragments (CYFRA 21-1), and tissue marker enzymes like aryl hydrocarbon hydroxylase, adenosine deaminase, γ-glutamyl transpeptidase, 5'-nucleotidase, and lactate dehydrogenase in serum and lung homogenate was carried out to substantiate the anticarcinogenic effect of BE. The overall data from our experiments suggested that BE significantly inhibited pulmonary adenoma formation and growth, thus revealing its potent antitumorigenic effect.

show abstract

“…As TPA is also elevated in several other diseases, it may not be specific for lung cancer. However, it has been suggested by Mumbarkar et al [87] that TPA and CYFRA 21-1 are useful serum markers for the diagnosis of NSCLC and their combined use may provide additional information for prognosis.…”

Section: Lung Cancer Protein Biomarkers In Serum: Current Statusmentioning

confidence: 99%

Serum-based protein biomarkers for detection of lung cancer

2014

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in terms of both incidence and mortality.The major reasons for the increasing number of deaths from lung cancer are late detection and lack of effective therapies. To improve our understanding of lung cancer biology, there is urgent need for blood-based, non-invasive molecular tests to assist in its detection in a cost-effective manner at an early stage when curative interventions are still possible. Recent advances in proteomic technology have provided extensive, high throughput analytical tools for identification, characterization and functional studies of proteomes. Changes in protein expression patterns in response to stimuli can serve as indicators or biomarkers of biological and pathological processes as well as physiological and pharmacological responses to drug treatment, thus aiding in early diagnosis and prognosis of disease. However, only a few biomarkers have been approved by the FDA to date for screening and diagnostic purposes. This review provides a brief overview of currently available proteomic techniques, their applications and limitations and the current state of knowledge about important serum biomarkers in lung cancer and their potential value as prognostic and diagnostic tools.

show abstract

Significance of tumor markers in lung cancer

Cited by 15 publications

References 7 publications

Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta‐analysis

Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta‐analysis

Potent antitumor and antineoplastic efficacy of baicalein on benzo(a)pyrene‐induced experimental pulmonary tumorigenesis

Serum-based protein biomarkers for detection of lung cancer

Contact Info

Product

Resources

About